Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Synlogic Inc
(NQ:
SYBX
)
1.400
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Synlogic Inc
< Previous
1
2
Next >
Synlogic Reports Second Quarter 2024 Financial Results
August 08, 2024
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Reports First Quarter 2024 Financial Results
May 14, 2024
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
March 19, 2024
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Adopts Limited Duration Stockholders Rights Plan
February 20, 2024
Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
February 08, 2024
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
February 02, 2024
From
Synlogic, Inc.
Via
GlobeNewswire
Sidoti Events, LLC's Virtual January Micro-Cap Conference
January 15, 2024
Via
ACCESSWIRE
Synlogic Provides Corporate Update and Outlook for 2024
January 04, 2024
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Contract with the Air Force Research Lab
December 27, 2023
- Selection of Synlogic reflects Company’s leadership in process development and manufacturing of therapeutics based on synthetic biology -
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
December 07, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
November 07, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
October 03, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
September 29, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism
September 28, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Reverse Stock Split
September 27, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic to Participate in Chardan’s Genetic Medicines Conference
September 21, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
September 19, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023
Recent milestones include initiation of the pivotal Phase 3 trial, Synpheny-3, and receipt of Fast Track designation for labafenogene marselecobac as a potential treatment for PKU
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
July 11, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces International Nonproprietary Name Selection for SYNB1934
June 28, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Participation in SVB Securities Healthcare Therapeutics Forum
June 27, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Reminds Stockholders of 2023 Annual General Meeting Details
June 08, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
June 05, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Announces Data Presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) Conference
May 24, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic to Present at the Jefferies Global Healthcare Conference
May 23, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
May 09, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
March 29, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1934 for the Treatment of Phenylketonuria
March 28, 2023
From
Synlogic, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.